MA53841A - Inhibiteurs pde9 de pyrazolopyrimidine - Google Patents

Inhibiteurs pde9 de pyrazolopyrimidine

Info

Publication number
MA53841A
MA53841A MA053841A MA53841A MA53841A MA 53841 A MA53841 A MA 53841A MA 053841 A MA053841 A MA 053841A MA 53841 A MA53841 A MA 53841A MA 53841 A MA53841 A MA 53841A
Authority
MA
Morocco
Prior art keywords
pyrazolopyrimidine
pde9 inhibitors
pde9
inhibitors
pyrazolopyrimidine pde9
Prior art date
Application number
MA053841A
Other languages
English (en)
French (fr)
Inventor
Ashok Arasappan
Jason M Cox
John S Debenham
Zhuyan Guo
Jiafang He
Zahid Hussain
Zhong Lai
Derun Li
Dongfang Meng
Subharekha Raghavan
Sriram Tyagarajan
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA53841A publication Critical patent/MA53841A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA053841A 2017-06-08 2018-06-06 Inhibiteurs pde9 de pyrazolopyrimidine MA53841A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762516903P 2017-06-08 2017-06-08
US201862665840P 2018-05-02 2018-05-02

Publications (1)

Publication Number Publication Date
MA53841A true MA53841A (fr) 2021-09-22

Family

ID=62779024

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053841A MA53841A (fr) 2017-06-08 2018-06-06 Inhibiteurs pde9 de pyrazolopyrimidine

Country Status (13)

Country Link
US (2) US10934294B2 (enExample)
EP (1) EP3634964B1 (enExample)
JP (1) JP2020523309A (enExample)
KR (1) KR20200013758A (enExample)
CN (1) CN111051308A (enExample)
AU (1) AU2018281131B2 (enExample)
BR (1) BR112019025813A2 (enExample)
CA (1) CA3064938A1 (enExample)
MA (1) MA53841A (enExample)
MX (1) MX2019014597A (enExample)
RU (1) RU2019144010A (enExample)
TW (1) TW201902898A (enExample)
WO (1) WO2018226771A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10934294B2 (en) * 2017-06-08 2021-03-02 Merck Sharp & Dohme Corp. Substituted pyrazolo[3,4-d]pyrimidines as PDE9 inhibitors
WO2020123271A1 (en) * 2018-12-12 2020-06-18 Merck Sharp & Dohme Corp. Cyclobutyl pyrazolopyrimidine pde9 inhibitors
WO2020123272A1 (en) * 2018-12-12 2020-06-18 Merck Sharp & Dohme Corp. Pyrazolopyrimidine pde9 inhibitors
AU2020235187B8 (en) * 2019-03-08 2024-02-08 Transthera Sciences (Nanjing), Inc. Uses of phosphodiesterase inhibitors
WO2021253180A1 (en) * 2020-06-15 2021-12-23 Novartis Ag Methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-4, 5, 6, 7-tetrahydro-1h-cyclopenta [b] pyridine-3-carboxylate and methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-1, 4, 5, 7-tetrahydrofuro [3, 4-b] pyridine-3-carboxylate as cav1.2 activators
CN114773256B (zh) * 2022-03-23 2024-05-03 中国农业大学 一种4-氰基哌啶的合成方法
CN117582909B (zh) * 2024-01-19 2024-04-02 天津凯莱英医药科技发展有限公司 一种连续生产5-单硝酸异山梨酯的系统和方法
CN120329388B (zh) * 2025-04-30 2025-09-26 中日友好医院(中日友好临床医学研究所) 一种双靶点多肽及其在心衰治疗中的应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE71183B1 (en) 1988-12-27 1997-01-29 Takeda Chemical Industries Ltd Guanidine derivatives their production and insecticides
US5294612A (en) 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
ES2233685T3 (es) 2000-08-01 2005-06-16 Bayer Healthcare Ag Inhibidores selectivos de pde 2 como medicamentos para mejorar la percepcion.
US6770645B2 (en) 2001-03-16 2004-08-03 Pfizer Inc. Pharmaceutically active compounds
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
HUP0401998A2 (hu) 2001-11-02 2005-01-28 Pfizer Products Inc., PDE9 inhibitorok alkalmazása olyan gyógyszer előállítására, amellyel inzulin-rezisztencia szindróma és 2-es típusú diabétesz kezelhető
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10328479A1 (de) 2003-06-25 2005-01-13 Bayer Ag 6-Arylamino-5-cyano-4-pyrimidinone
US8293754B2 (en) 2005-06-14 2012-10-23 Aska Pharmaceutical Co., Ltd. Thienopyrimidine derivatives
CA2914168C (en) 2006-03-28 2018-05-08 Atir Holding S.A. Pyrido[1,2-a]pyrimidin-4-one derivatives and their use in the treatment of sexual disorders
US8101624B2 (en) 2006-08-08 2012-01-24 Aska Pharmaceutical Co., Ltd. Quinazoline derivatives
KR101563103B1 (ko) 2006-12-13 2015-10-23 아스카 세이야쿠 가부시키가이샤 퀴녹살린 유도체
AU2008249750B2 (en) 2007-05-11 2011-07-14 Pfizer Inc. Amino-heterocyclic compounds
US8648085B2 (en) 2007-11-30 2014-02-11 Boehringer Ingelheim International Gmbh 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders
US9089572B2 (en) 2008-01-17 2015-07-28 California Institute Of Technology Inhibitors of p97
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
JP5453431B2 (ja) 2008-09-08 2014-03-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピラゾロピリミジン及びcns障害の治療のためのそれらの使用
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基-雜環化合物
PT2414363E (pt) 2009-03-31 2014-02-26 Boehringer Ingelheim Int Derivados de 1-heterociclil-1,5-di-hidro-pirazolo[3,4- d]pirimidin-4-ona e sua utilização como moduladores de pde9a
TW201118099A (en) 2009-08-12 2011-06-01 Boehringer Ingelheim Int New compounds for the treatment of CNS disorders
NZ603725A (en) * 2010-08-12 2015-04-24 Boehringer Ingelheim Int 6-cycloalkyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
JP5990106B2 (ja) 2011-01-28 2016-09-07 佐藤製薬株式会社 縮環化合物
US20130040971A1 (en) * 2011-02-14 2013-02-14 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
EP2906562B1 (en) 2011-10-10 2016-10-05 H. Lundbeck A/S Pde9i with imidazo pyrazinone backbone
TW201348231A (zh) 2012-02-29 2013-12-01 Amgen Inc 雜雙環化合物
KR101706216B1 (ko) 2012-04-03 2017-02-13 한화테크윈 주식회사 고밀도 삼차원 영상 재구성 장치 및 방법
WO2014024125A1 (en) 2012-08-08 2014-02-13 Celon Pharma S.A. Pyrazolo[4,3-d]pyrimidin-7(6h)-one derivatives as pde9 inhibitors
US10174032B2 (en) 2014-05-05 2019-01-08 Signalrx Pharmaceuticals, Inc. Heterocyclic compound classes for signaling modulation
WO2016191935A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016209749A1 (en) 2015-06-25 2016-12-29 Merck Sharp & Dohme Corp. Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors
WO2017000276A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclic heterocyclic compounds as pde2 inhibitors
US10376504B2 (en) 2015-07-29 2019-08-13 Merck, Sharp & Dohme Corp. Substituted quinolinones as PDE9 inhibitors
WO2017019724A1 (en) 2015-07-29 2017-02-02 Merck Sharp & Dohme Corp. Phenyl-cyanoquinolinone pde9 inhibitors
WO2017019726A1 (en) 2015-07-29 2017-02-02 Merck Sharp & Dohme Corp. Oxy-cyanoquinolinone pde9 inhibitors
US10934294B2 (en) * 2017-06-08 2021-03-02 Merck Sharp & Dohme Corp. Substituted pyrazolo[3,4-d]pyrimidines as PDE9 inhibitors

Also Published As

Publication number Publication date
US11028092B2 (en) 2021-06-08
JP2020523309A (ja) 2020-08-06
BR112019025813A2 (pt) 2020-07-07
US20200140445A1 (en) 2020-05-07
KR20200013758A (ko) 2020-02-07
MX2019014597A (es) 2020-02-05
US10934294B2 (en) 2021-03-02
RU2019144010A3 (enExample) 2021-10-01
EP3634964B1 (en) 2022-02-23
WO2018226771A1 (en) 2018-12-13
TW201902898A (zh) 2019-01-16
AU2018281131A1 (en) 2019-12-05
RU2019144010A (ru) 2021-07-13
AU2018281131B2 (en) 2022-01-20
CA3064938A1 (en) 2018-12-13
US20180354955A1 (en) 2018-12-13
CN111051308A (zh) 2020-04-21
EP3634964A1 (en) 2020-04-15

Similar Documents

Publication Publication Date Title
EP3541932A4 (en) INHIBITORS OF CRISPR-CAS9
EP3347008A4 (en) BETA-Lactamase INHIBITORS
EP3442974C0 (en) Pyrazolopyrimidine derivatives
MA52812A (fr) Inhibiteurs de sarm1
MA47301A (fr) Inhibiteurs sélectifs de jak1
MA52814A (fr) Inhibiteurs de bromodomaine
SI4074703T1 (sl) Piridinil-(aza)indolsulfonamidi
MA53841A (fr) Inhibiteurs pde9 de pyrazolopyrimidine
DK3681884T3 (da) Rad51-inhibitorer
EP3313828A4 (en) METALLO-BETA-Lactamase INHIBITORS
MA44006A (fr) Inhibiteur pde1
CL2016002638A1 (es) Nuevos inhibidores de la nitrificación
EP3801499A4 (en) INHIBITORS OF SARM1
EP3817736A4 (en) PIKFYVE INHIBITORS
EP3722298A4 (en) PYRROLO DERIVATIVE (PYRAZOLO) PYRIMIDINE USED AS LRRK2 INHIBITOR
EP3394068A4 (en) TDO2 INHIBITORS
DK3630744T3 (da) Pyrazol-magl-inhibitorer
EP3712287A4 (en) COMPONENT TREATED BY NITRATION
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
MA46280A (fr) Inhibiteurs de la dopamine-b-hydroxylase
EP3600301A4 (en) KDM4 INHIBITORS
EP3661935A4 (en) SUBSTITUTED PYRAZOLOPYRIMIDINES THAT MAY BE USED AS KINASE INHIBITORS
EP3621837C0 (en) MOBILE HOSTING
MA51611A (fr) Inhibiteurs de pi4kiiibêta
EP3697821A4 (en) PROCESS